Novavax cuts 2024 revenue forecast
Hosted on MSN9h
Novavax’s stock slides 7% as guidance cut offsets narrower-than-expected third-quarter lossNovavax Inc.’s stock fell 4% Tuesday after the company cut its full-year guidance, offsetting a narrower-than-expected ...
Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its Covid ...
FY24 consensus $761.46M. Cuts FY24 product sales view to $175M-$225M from $275M-$375M. Raises FY24 Licensing, Royalties and Other Revenue view ...
The US Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug (IND) application for ...
The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...
Shares of Novavax Inc. NVAX slid 6.10% to $8.46 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.09% to ...
6h
H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Novavax (NVAX – Research Report) today and set a price target of ...
Good morning and welcome to Novavax' Third Quarter 2024 Financial Results and Operational Highlights Conference Call. All participants will be in listen-only mode. [Operator Instructions] After ...
GAITHERSBURG, Md. (AP) — GAITHERSBURG, Md. (AP) — Novavax Inc. (NVAX) on Tuesday reported a loss of $121.3 million in its third quarter. On a per-share basis, the Gaithersburg, Maryland-based company ...
Novavax's (NVAX) stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for ...
Hosted on MSN6h
Novavax Stock Dives Even Though Results Beat ForecastsNovavax stock fell sharply after the pharmaceutical company cut its forecast for annual revenue despite ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback